'Quidel Cardiovascular Inc. Recalls Quidel Triage Cardiac Panels For Risk Of False Negative Troponin Results That Could Cause Delayed Diagnosis Or Missed Myocardial Infarction'
Portfolio Pulse from Happy Mohamed
Quidel Cardiovascular Inc. is recalling its Quidel Triage Cardiac Panel due to the risk of false negative troponin results that could lead to delayed or missed diagnosis of myocardial infarction. The FDA has classified this as a Class I recall, the most serious type. The company has reported 41 complaints but no injuries or deaths related to this issue. The recall affects 7,799 devices in the U.S. distributed since November 1, 2022.
July 17, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Quidel Corporation (QDEL) is facing a Class I recall of its Quidel Triage Cardiac Panel due to the risk of false negative results. This could potentially harm the company's reputation and sales.
The recall of a product, especially a Class I recall, can have significant negative impacts on a company. It can damage the company's reputation, lead to financial losses due to the costs of the recall, and potentially result in decreased sales if customers lose trust in the company's products. Therefore, this news is likely to have a negative impact on QDEL's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100